Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cellectis S.A. ADR
(NQ:
CLLS
)
2.380
+0.010 (+0.42%)
Streaming Delayed Price
Updated: 10:14 AM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cellectis S.A. ADR
< Previous
1
2
3
4
5
6
Next >
Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023
May 17, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors
May 12, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
May 11, 2023
BALLI-01 (evaluating UCART22) abstract demonstrates safety and preliminary efficacy of UCART22 in heavily pretreated r/r B-ALL population
From
Cellectis Inc.
Via
GlobeNewswire
Recap: Cellectis Q1 Earnings
May 04, 2023
Via
Benzinga
Expert Ratings for Cellectis
April 05, 2023
Via
Benzinga
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023
May 04, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 02, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
April 27, 2023
From
Cellectis Inc.
Via
GlobeNewswire
A Preview Of Cellectis's Earnings
March 07, 2023
Via
Benzinga
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
April 24, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting
April 17, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22
April 11, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million
April 04, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
March 14, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 08, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Earnings Scheduled For March 8, 2023
March 08, 2023
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.
Via
Benzinga
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
March 06, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
March 01, 2023
From
Cellectis Inc.
Via
GlobeNewswire
There's a Lot of Upside For Emerging Gene-Editing Companies
February 21, 2023
These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come.
Via
MarketBeat
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
February 07, 2023
From
Cellectis Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
February 03, 2023
Via
Benzinga
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
February 03, 2023
From
Cellectis Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 03, 2023
Via
Benzinga
Cellectis Announces Pricing of Follow-On Offering
February 03, 2023
From
Cellectis Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
February 02, 2023
Via
Benzinga
Cellectis Announces Launch of Follow-On Offering
February 02, 2023
From
Cellectis Inc.
Via
GlobeNewswire
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.
Via
InvestorPlace
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
January 20, 2023
From
Cellectis Inc.
Via
GlobeNewswire
Why Is Calyxt (CLXT) Stock Up 140% Today?
January 17, 2023
Calyxt (CLXT) stock is rocketing higher on Tuesday after the company signed an all-stock merger agreement with Cibus Global.
Via
InvestorPlace
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
January 17, 2023
From
Cellectis Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.